Specialised lipid mediators and their targets

Seminars in Immunology

Volumn 27, Issue 3, 2015, Pages 169-176

  Crean, Daniel ^a   Godson, Catherine ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Inflammation; Lipid mediators; Resolution

Indexed keywords

ADIPONECTIN; CD59 ANTIGEN; CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 6; LEUKOTRIENE; LIPID; LIPOXIN; MARESIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROSTAGLANDIN E2; PROTEIN; RESOLVIN; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; DOCOSAHEXAENOIC ACID;

CYTOKINE PRODUCTION; DENDRITIC CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; CHRONIC DISEASE; HOMEOSTASIS; HUMAN; IMMUNOLOGY;

CHRONIC DISEASE; CYTOKINES; DOCOSAHEXAENOIC ACIDS; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOXINS;

EID: 84937518824     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2015.05.002     Document Type: Review

References (119)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
2. Kohli P., Levy B.D. Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 2009, 158:960-971.
3. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defences. Clin. Microbiol. Rev. 2009, 22:240-273.
4. Serhan C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014, 510:92-101.
5. Maderna P., Godson C. Lipoxins: resolutionary road. Br. J. Pharmacol. 2009, 158:947-959.
6. Buckley C.D., Gilroy D.W., Serhan C.N. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity 2014, 40:315-327.
7. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ. Res. 2010, 107:1170-1184.
8. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
9. Seibel M.J., Cooper M.S., Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013, 1:59-70.
10. Plasencia C., Pascual-Salcedo D., García-Carazo S., Lojo L., Nuño L., Villalba A., Peiteado D., Arribas F., Díez J., López-Casla M.T., Martín-Mola E., Balsa A. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res. Ther. 2013, 15:R79.
11. Buttgereit F., Smolen J.S., Coogan A.N., Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. Nat. Rev. Rheumatol. 2015, 10.1038/nrrheum.2015.31.
12. Rafacho A., Ortsäter H., Nadal A., Quesada I. Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J. Endocrinol. 2014, 223:R49-R62.
13. Keane J., Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr. Opin. Rheumatol. 2008, 20:443-449.
14. Szabo A., Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immuneresponses. Am. J. Clin. Exp. Immunol. 2013, 2:195-207.
15. Wu J., Chen Z.J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 2014, 32:461-488.
16. Rock K.L., Latz E., Ontiveros F., Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 2010, 28:321-342.
17. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003, 52:1256-1264.
18. Lin M., Yiu W.H., Wu H.J., Chan L.Y., Leung J.C., Au W.S., Chan K.W., Lai K.N., Tang S.C. Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23:86-102.
19. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aljada A., Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887.
20. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 2002, 195:99-111.
21. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., Khoury J.E., Golenbock D.T., Moore K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
22. Szatmary Z. Molecular biology of toll-like receptors. Gen. Physiol. Biophys. 2012, 31:357-366.
23. Kawai T., Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 2009, 21:317-337.
24. Schaefer L. Complexity of danger: the diverse nature of damage-associated molecular patterns. J. Biol. Chem. 2014, 289:35237-35245.
25. Hayden M.S., Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012, 26:203-234.
26. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
27. Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1:a001651.
28. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby D.A. Possible new role for NF-κB in the resolution of inflammation. Nat. Med. 2001, 7:1291-1297.
29. Lämmermann T., Afonso P.V., Angermann B.R., Wang J.M., Kastenmüller W., Parent C.A., Germain R.N. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 2013, 498:371-375.
30. Godson C., Mitchell S., Harvey K., Petasis N.A., Hogg N., Brady H.R. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 2000, 164:1663-1667.
31. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G., Petasis N.A., Erwig L., Rees A.J., Savill J., Brady H.R., Godson C. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 2002, 13:2497-2507.
32. Rodgers K., McMahon B., Mitchell D., Sadlier D., Godson C. Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am. J. Pathol. 2005, 167:683-694.
33. Börgeson E., Docherty N.G., Murphy M., Rodgers K., Ryan A., O'Sullivan T.P., Guiry P.J., Goldschmeding R., Higgins D.F., Godson C. Lipoxin A4 and benzo-lipoxin A4 attenuate experimental renal fibrosis. FASEB J. 2011, 25:2967-2979.
34. Brennan E.P., Nolan K.A., Börgeson E., Gough O.S., McEvoy C.M., Docherty N.G., Higgins D.F., Murphy M., Sadlier D.M., Ali-Shah S.T., Guiry P.J., Savage D.A., Maxwell A.P., Martin F., Godson C. GENIE Consortium, Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J. Am. Soc. Nephrol. 2013, 24:627-637. GENIE Consortium.
35. Schwab J.M., Chiang N., Arita M., Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874.
36. Chan M.M., Moore A.R. Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol. 2010, 184:6418-6426.
37. Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta 2014, 1843:2563-2582.
38. Hayden M.S., Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin. Immunol. 2014, 26:253-266.
39. Commins S.P., Borish L., Steinke J.W. Immunologic messenger molecules: cytokines, interferons, and chemokines. J. Allergy Clin. Immunol. 2010, 125:S53-S72.
40. Sabio G., Davis R.J. TNF and MAP kinase signalling pathways. Semin. Immunol. 2014, 26:237-245.
41. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
42. Zaslona Z., Serezani C.H., Okunishi K., Aronoff D.M., Peters-Golden M. Prostaglandin E2 restrains macrophage maturation via E prostanoid receptor 2/protein kinase A signaling. Blood 2012, 119:2358-2367.
43. Legler D.F., Bruckner M., Uetz-von Allmen E., Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. J. Biochem. Cell Biol. 2010, 42:198-201.
44. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294:1871-1875.
45. Scully M., Gang C., Condron C., Bouchier-Hayes D., Cunningham A.J. Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect. J. Surg. Res. 2012, 175:176-184.
46. Markworth J.F., Vella L., Lingard B.S., Tull D.L., Rupasinghe T.W., Sinclair A.J., Maddipati K.R., Cameron-Smith D. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013, 305:R1281-R1296.
47. Funk C.D., FitzGerald G.A. COX-2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 2007, 50:470-479.
48. Grosser T., Yu Y., Fitzgerald G.A. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 2010, 61:17-33.
49. Spektor G., Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now. Nat. Clin. Pract. Cardiovasc. Med. 2005, 2:290-300.
50. Marnett L.J. Mechanisms of cyclooxygenase-2 inhibition and cardiovascular side effects: the plot thickens. Cancer Prev. Res. 2009, 2:288-290.
51. Kast R.E., Tenofovir COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation. Mol. Immunol. 2003, 40:297-303.
52. Kanaoka Y., Boyce J.A. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol. Res. 2014, 6:288-295.
53. Liu M., Yokomizo T. The role of leukotrienes in allergic diseases. Allergol. Int. 2015, 64:17-26.
54. Serezani C.H., Lewis C., Jancar S., Peters-Golden M. Leukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression. J. Clin. Invest. 2011, 121:671-682.
55. Wang Z., Filgueiras L.R., Wang S., Serezani A.P., Peters-Golden M., Jancar S., Serezani C.H. Leukotriene B4 enhances the generation of proinflammatory microRNAs to promote MyD88-dependentmacrophage activation. J. Immunol. 2014, 192:2349-2356.
56. Li P., Oh da Y., Bandyopadhyay G., Lagakos W.S., Talukdar S., Osborn O., Johnson A., Chung H., Mayoral R., Maris M., Ofrecio J.M., Taguchi S., Lu M., Olefsky J.M. LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat. Med. 2015, 21:239-247.
57. Börgeson E., Godson C. Molecular circuits of resolution in renal disease. Sci. World J. 2010, 10:1370-1385.
58. Serhan C.N., Hamberg M., Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Res. Commun. 1984, 118:943-949.
59. Patrignani P., Dovizio M. Inside platelet-leukocyte cross-talk. Blood 2012, 119:3649-3650.
60. Maddox J.F., Hachicha M., Takano T., Petasis N.A., Fokin V.V., Serhan C.N. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J. Biol. Chem. 1997, 272:6972-6978.
61. Börgeson E., Lönn J., Bergström I., Brodin V.P., Ramström S., Nayeri F., Särndahl E., Bengtsson T. Lipoxin A4 inhibits porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. Infect. Immun. 2011, 79:1489-1497.
62. Börgeson E., Godson C. Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol. 2012, 3:318.
63. Maderna P., Cottell D.C., Toivonen T., Dufton N., Dalli J., Perretti M., Godson C. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J. 2010, 24:4240-4249.
64. Perretti M., D'Acquisto F. Novel aspects of annexin 1 and glucocorticoid biology: intersection with nitric oxide and the lipoxin receptor. Inflamm. Allergy Drug Targets 2006, 5:107-114.
65. Gavins F.N., Sawmynaden P., Chatterjee B.E., Perretti M. A twist in anti-inflammation: annexin 1 acts via the lipoxin A4 receptor. Prostaglandin Leukot. Essent. Fatty Acids 2005, 73:211-219.
66. Su S.B., Gong W., Gao J.L., Shen W., Murphy P.M., Oppenheim J.J., Wang J.M. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 1999, 189:395-402.
67. Chiang N., Fierro I.M., Gronert K., Serhan C.N. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J. Exp. Med. 2000, 191:1197-1208.
68. Cooray S.N., Gobbetti T., Montero-Melendez T., McArthur S., Thompson D., Clark A.J., Flower R.J., Perretti M. Ligand-specific conformational change of the G-protein-coupled receptor ALX/FPR2 determines proresolving functional responses. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:18232-18237.
69. Walker J., Dichter E., Lacorte G., Kerner D., Spur B., Rodriguez A., Yin K. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 2011, 36:410-416.
70. Gewirtz A.T., Collier-Hyams L.S., Young A.N., Kucharzik T., Guilford W.J., Parkinson J.F., Williams I.R., Neish A.S., Madara J.L. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 2002, 168:5260-5267.
71. Conte F.P., Menezes-de-Lima O., Verri W.A., Cunha F.Q., Penido C., Henriques M.G. Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects. Br. J. Pharmacol. 2010, 161:911-924.
72. Xu Z., Zhao F., Lin F., Xiang H., Wang N., Ye D., Huang Y. Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator. Fertil. Steril. 2014, 102:282-290.
73. Morris T., Stables M., Hobbs A., de Souza P., Colville-Nash P., Warner T., Newson J., Bellingan G., Gilroy D.W. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 2009, 183:2089-2096.
74. Wu S.H., Chen X.Q., Liu B., Wu H.J., Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br. J. Dermatol. 2013, 168:172-178.
75. Brancaleone V., Gobbetti T., Cenac N., le Faouder P., Colom B., Flower R.J., Vergnolle N., Nourshargh S., Perretti M. A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 2013, 122:608-617.
76. Gobbetti T., Coldewey S.M., Chen J., McArthur S., le Faouder P., Cenac N., Flower R.J., Thiemermann C., Perretti M. Nonredundant protective properties of FPR2/ALX in polymicrobial murine sepsis. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:18685-18690.
77. Pierdomenico A.M., Recchiuti A., Simiele F., Codagnone M., Mari V.C., Davì G., Romano M. MicroRNA-181b regulates ALX/FPR2 receptor expression and pro resolution signaling in human macrophages. J. Biol. Chem. 2015, 290:3592-3600.
78. McMahon B., Mitchell D., Shattock R., Martin F., Brady H.R., Godson C. Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 2002, 16:1817-1819.
79. Mitchell D., O'Meara S.J., Gaffney A., Crean J.K., Kinsella B.T., Godson C. The lipoxin A4 receptor is coupled to SHP-2 activation: implications for regulation of receptor tyrosine kinases. J. Biol. Chem. 2007, 282:15606-15618.
80. Zhou X.Y., Yu Z.J., Yan D., Wang H.M., Huang Y.H., Sha J., Xu F.Y., Cai Z.Y., Min W.P. BML-11, a lipoxin receptor agonist, protected carbon tetrachloride-induced hepatic fibrosis in rats. Inflammation 2013, 36:1101-1106.
81. Martins V., Valença S.S., Farias-Filho F.A., Molinaro R., Simões R.L., Ferreira T.P., e Silva P.M., Hogaboam C.M., Kunkel S.L., Fierro I.M., Canetti C., Benjamim C.F. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J. Immunol. 2009, 182:5374-5381.
82. Börgeson E., McGillicuddy F.C., Harford K.A., Corrigan N., Higgins D.F., Maderna P., Roche H.M., Godson C. Lipoxin A4 attenuates adipose inflammation. FASEB J. 2012, 26:4287-4294.
83. Borgeson E., Johnston A., Lee Y.S., Till A., Syed G.H., Ali Shah T., Guiry P.J., Dalli J., Colas R., Serhan C.N., Sharma K., Godson C. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metab. 2015, 10.1016/j.cmet.2015.05.003.
84. Titos E., Clària J. Omega-3-derived mediators counteract obesity-induced adipose tissue inflammation. Prostaglandins Other Lipid Mediat. 2013, 107:77-84.
85. Spite M., Clària J., Serhan C.N. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014, 19:21-36.
86. Tai H.H., Ensor C.M., Tong M., Zhou H., Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat. 2002, 68-69:483-493.
87. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8247-8252.
88. Duffy C.D., Maderna P., McCarthy C., Loscher C.E., Godson C., Guiry P.J. Synthesis and biological evaluation of pyridine-containing lipoxin A4 analogues. ChemMedChem 2010, 5:517-522.
89. Canny G., Levy O., Furuta G.T., Narravula-Alipati S., Sisson R.B., Serhan C.N., Colgan S.P. Lipid mediator-induced expression of bactericidal/permeability-increasing protein (BPI) in human mucosal epithelia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3902-3907.
90. Aliberti J., Serhan C., Sher A. Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 2002, 196:1253-1262.
91. 4-mediated effect. PLoS Negl. Trop. Dis. 2013, 7:e2173.
92. Tobin D.M., Vary J.C., Ray J.P., Walsh G.S., Dunstan S.J., Bang N.D., Hagge D.A., Khadge S., King M.C., Hawn T.R., Moens C.B., Ramakrishnan L. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010, 140:717-730.
93. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fattyacids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000, 192:1197-1204.
94. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 2002, 21:495-505.
95. Simopoulos A.P. Omega-3 fatty acids in the prevention-management of cardiovascular disease. Can. J. Physiol. Pharmacol. 1997, 75:234-239.
96. Arita M., Bianchini F., Aliberti J., Sher A., Chiang N., Hong S., Yang R., Petasis N.A., Serhan C.N. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201:713-722.
97. Hasturk H., Kantarci A., Ohira T., Arita M., Ebrahimi N., Chiang N., Petasis N.A., Levy B.D., Serhan C.N., Van Dyke T.E. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 2006, 20:401-403.
98. Herrera B.S., Hasturk H., Kantarci A., Freire M.O., Nguyen O., Kansal S., Van Dyke T.E. Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect. Immun. 2015, 83:792-801.
99. Herová M., Schmid M., Gemperle C., Hersberger M. ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages. J. Immunol. 2015, 194:2330-2337.
100. Tjonahen E., Oh S.F., Siegelman J., Elangovan S., Percarpio K.B., Hong S., Arita M., Serhan C.N. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 2006, 13:1193-1202.
101. Ogawa S., Urabe D., Yokokura Y., Arai H., Arita M., Inoue M. Total synthesis and bioactivity of resolvin E2. Org. Lett. 2009, 11:3602-3605.
102. Oh S.F., Dona M., Fredman G., Krishnamoorthy S., Irimia D., Serhan C.N. Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 2012, 188:4527-4534.
103. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196:1025-1037.
104. Akagi D., Chen M., Toy R., Chatterjee A., Conte M.S. Systemic delivery of pro resolving lipid mediators resolvin D2 maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015, pii: fj.14-265363.
105. Titos E., Rius B., González-Périz A., López-Vicario C., Morán-Salvador E., Martínez-Clemente M., Arroyo V., Clària J. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J. Immunol. 2011, 187:5408-5418.
106. Krishnamoorthy S., Recchiuti A., Chiang N., Yacoubian S., Lee C.H., Yang R., Petasis N.A., Serhan C.N. Resolvin D1 binds human phagocytes with evidence for pro resolving receptors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1660-1665.
107. Krishnamoorthy S., Recchiuti A., Chiang N., Fredman G., Serhan C.N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and pro resolving microRNAs. Am. J. Pathol. 2012, 180:2018-2027.
108. Park C.K., Xu Z.Z., Liu T., Lü N., Serhan C.N., Ji R.R. Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. J. Neurosci. 2011, 31:18433-18438.
109. Al-Zaubai N., Johnstone C.N., Leong M.M., Li J., Rizzacasa M., Stewart A.G. Resolvin D2 supports MCF-7 cell proliferation via activation of estrogen receptor. J. Pharmacol. Exp. Ther. 2014, 351(1):172-180.
110. Stewart A.G. Mediators and receptors in the resolution of inflammation: drug targeting opportunities. Br. J. Pharmacol. 2009, 158:933-935.
111. Duffield J.S., Hong S., Vaidya V.S., Lu Y., Fredman G., Serhan C.N., Bonventre J.V. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 2006, 177:5902-5911.
112. White P.J., Mitchell P.L., Schwab M., Trottier J., Kang J.X., Barbier O., Marette A. Transgenic ω-3 PUFA enrichment alters morphology and gene expression profile in adipose tissue of obese mice: potential role for protectins. Metabolism 2015, 64:666-676.
113. González-Périz A., Horrillo R., Ferré N., Gronert K., Dong B., Morán-Salvador E., Titos E., Martínez-Clemente M., López-Parra M., Arroyo V., Clària J. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J. 2009, 23:1946-1957.
114. Ariel A., Fredman G., Sun Y.P., Kantarci A., Van Dyke T.E., Luster A.D., Serhan C.N. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 2006, 7:1209-1216.
115. Serhan C.N., Yang R., Martinod K., Kasuga K., Pillai P.S., Porter T.F., Oh S.F., Spite M. Maresins: novel macrophage mediators with potent anti-inflammatory and pro resolving actions. J. Exp. Med. 2009, 206:15-23.
116. Deng B., Wang C.W., Arnardottir H.H., Li Y., Cheng C.Y., Dalli J., Serhan C.N. Maresin biosynthesis and identification of maresin 2, a new anti-inflammatory and pro-resolving mediator from human macrophages. PLOS ONE 2014, 9:e102362.
117. Gong J., Wu Z.Y., Qi H., Chen L., Li H.B., Li B., Yao C.Y., Wang Y.X., Wu J., Yuan S.Y., Yao S.L., Shang Y. Maresin 1 mitigates LPS-induced acute lung injury in mice. Br. J. Pharmacol. 2014, 171:3539-3550.
118. Marcon R., Bento A.F., Dutra R.C., Bicca M.A., Leite D.F., Calixto J.B. Maresin 1, a pro resolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J. Immunol. 2013, 191:4288-4298.
119. Chatterjee A., Sharma A., Chen M., Toy R., Mottola G., Conte M.S. The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. PLOS ONE 2014, 9:e113480.